A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received Pfizer Inc's (NYSE: PFE) COVID-19 vaccine, Moderna Inc (NASDAQ: MRNA) vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations.
Lower risk was observed across all age groups, comorbidity-burden categories, and race.
Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer's BNT162b2 "in risk of infection or hospitalization were progressively greater when the follow-up period was longer."
The study evaluated over 900,000 vaccine recipients, followed for a mean of 192 days, during which there were almost 17,000 infections, more than 3,500 hospitalizations, and 381 deaths.
While fewer patients who received Moderna's vaccine died than Pfizer (168 versus 213), the researchers said this difference was not statistically significant.
Price Action: PFE stock is up 0.17% at $56.32, MRNA stock is down 4.63% at $222.88 during the market session on the last check Tuesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.